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Background
Numerous studies introduced epidermal keratinocytes as ‘non-
classical’ immune-competent cells, hence potent primary regula-
tors and active participants of cutaneous immune functions (1),
(s1–6). Therefore, targeting them might provide a novel, highly
specific anti-inflammatory therapeutic possibility. The endo-
cannabinoid system (ECS) is an emerging signalling network
which regulates multiple cutaneous functions (2,3). The loss of
homoeostatic endocannabinoid (eCB) signalling of epidermal ker-
atinocytes was shown to dramatically enhance inflammatory pro-
cesses, arguing for that the cutaneous eCB tone plays a ‘gate-
keeper’ role in the initiation phase of skin inflammation (4); for
further details see Supplementary Background section). Moreover,
elevation of the eCB tone, for example by the inhibition of fatty
acid amide hydrolase (FAAH), the most important enzyme
engaged with the degradation of the eCB anandamide (AEA); (5),
exerts ECS-mediated anti-inflammatory actions in multiple
organs (5).
Questions addressed
Based on these data, we hypothesized that upregulation of expres-
sion/activity of FAAH [thereby decreasing the eCB tone, and
increasing the level of the pro-inflammatory ‘eCB degradation
product’ arachidonic acid (AA)] might contribute to the develop-
ment of the inflammatory processes. Therefore, we aimed at inves-
tigating (i) mRNA and protein expressions and activity of FAAH
in human keratinocytes in Toll-like receptor (TLR)-induced
inflammation models and (ii) the suggested anti-inflammatory
effects of two newly developed, potent and selective N-alkylcarba-
mate FAAH inhibitors WOBE440 (IC50 = 25  8 nM) and
WOBE479 (IC50 = 78  13 nM) (Fig. S1) which show high speci-
ficity over other known targets within the ECS [IC50 > 10 lM for
cannabinoid receptor (CNR)-1, CNR2, monoacylglycerol lipase
and the putative endocannabinoid membrane transporter] (6) on
primary (NHEK) and immortalized (HPV-KER) (7,8) human epi-
dermal keratinocytes as well as in NC/Tnd mice, a widely used
animal model of atopic dermatitis (AD) (9).
Experimental design
Detailed description of the methods can be found in the Supple-
mentary Experimental design section.
Cell culture
Human skin samples were obtained after obtaining written
informed consent from healthy individuals, adhering to Helsinki
guidelines, and after obtaining permissions from respective institu-
tional and government bodies (protocol No.: DE OEC RKEB/
IKEB 3724-2012; document No.: IX-R-052/01396-2/2012).
Determination of cellular viability, apoptosis and necrosis
Viability and cell death were determined by MTT and DilC1(5)-
SYTOX Green assays as described previously (s11).
Expression analysis
Molecular expression was monitored by Q-PCR and Western blot
as described previously with slight modifications (s11). The
released amount of IL6 and IL8 was determined using OptEIA kits
(BD Pharmingen, Franklin Lakes, NJ, USA) according to the man-
ufacturer’s protocol.
Determination of the FAAH activity
The enzymatic activity of FAAH in NHEK and HPV-KER
homogenates was assessed by determination of the hydrolysis of
[ethanolamine-1-3H]AEA as previously described (s12–16).
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Experiments on NC/Tnd mice
The study was conducted at BioTox Sciences (BTS; San Diego,
CA, USA). The study design and animal usage were reviewed and
approved by the Institutional Animal Care and Use Committee
(IACUC; No. 1109-05). Clinical score was determined from obser-
vations of the upper back/lower neck with a scale of 0–3 (0:
absent; 1: mild; 2: moderate; 3: severe) for erythema, oedema or
papulations, and for oozing, crusts or haemorrhages. Each mouse
received a single daily topical dose that was applied to the upper
back/lower neck area.
Statistical analysis
Data were analysed and graphs were plotted by using Origin Pro
Plus 6.0 software (Microcal, Northampton, MA, USA), using Stu-
dent’s two-tailed two samples t-test and P < 0.05 values were
regarded as significant differences.
Results
We found that FAAH is expressed in HPV-KERs both at the
mRNA and protein levels (Fig. S2; Fig. 1a–b). Importantly, we
also found that upon administration of TLR2 or -4 activators
[lipoteichoic acid (LTA) and lipopolysaccharide (LPS), respec-
tively], expression of FAAH at the protein level tended to be
increased. Interestingly, at the mRNA level, only 3-hr LPS treat-
ment induced significant increase (Figs. 1a–b, S2), and in NHEKs,
only LTA was able to enhance the expression (Fig. 1c–d). Impor-
tantly, both HPV-KERs and NHEKs exhibited significant eleva-
tions in FAAH activity upon TLR2 activation (Fig. 1e–f). The
above findings raised the possibility that the decreased eCB tone
mediated by FAAH upregulation might theoretically contribute to
the development of the TLR-activation-induced pro-inflammatory
responses in the human skin. To challenge this hypothesis, next,
we investigated the putative anti-inflammatory effects of selective
FAAH inhibitors, by monitoring the production of key pro-
inflammatory cytokines (IL1A, IL1B, IL6 and IL8; s17–19). As
expected, both the commercially available FAAH inhibitor
URB597 (s20), as well as novel inhibitors (WOBE440 and
WOBE479) almost completely prevented the LTA-induced upreg-
ulation of the aforementioned cytokines (Fig. 2a–b). Importantly,
they also significantly suppressed the LTA-induced release of IL6
and IL8 (Fig. 2c–d). FAAH inhibitors exert their effects via the
elevation of the local AEA tone, which subsequently activates
CNR1 and CNR2 (5). In a good agreement with the literature data
(4), combined antagonism of these receptors markedly abolished
the anti-inflammatory actions of the FAAH inhibitors (Fig. S3).
Importantly, concentrations of FAAH inhibitors having been pro-
ven to exert anti-inflammatory actions (i.e. 100 and 200 nM for
WOBE440 and WOBE479, respectively) did not induce any mea-
surable cytotoxicity when applied either in short-term (8 and
24 h; Fig. S4a–d) or in long-term experiments (72 h; Fig. S5a–b),
indicating that they can most probably be administered without
the risk of significant cutaneous cytotoxicity. Finally, we aimed at
investigating the putative in vivo efficiency of the FAAH inhibi-
tors, employing a widely accepted animal model of AD, that is the
NC/Tnd mice (9). After appropriate antigen exposure and the
development of AD-like cutaneous symptoms, mice were treated
with the novel FAAH inhibitors or vehicle, as described in the
Supplementary Experimental Design section. As a ‘positive’ con-
trol, tacrolimus ointment (Protopic; commonly administered in
the treatment of AD; s21) was used. Of great importance, FAAH
inhibitors significantly reduced both the total disease score (for
details, see Supplementary Experimental design section) and ear
thickness. It is also important to note that beneficial effects of the
FAAH inhibitors were comparable to those exerted by tacrolimus
(Figs. 2e–f; S6a–d) and that no (obvious macroscopic or beha-
vioural) side effects developed during the 1-month-long drug
administration. These data strongly suggest that inhibition of
FAAH results in substantial anti-inflammatory actions in vivo as
well.
Conclusions
For detailed discussion, see Supplementary Conclusion section 1.
Taken together, our results introduce FAAH as an important,
TLR2-dependent regulator of cutaneous inflammatory processes
(Fig. S7a–b). Thus, according to our translationally relevant, com-
plementary in vitro and in vivo data, local inhibition of FAAH
could provide a highly targeted and hence most probably side
effect-free tool for mitigating cutaneous inflammation (further
discussion of the expected beneficial effects can be found in the
Supplementary Conclusion section 2). Therefore, these data
should encourage one to test, next in appropriate clinical trials the
in vivo efficiency of the FAAH inhibitors in the management of
inflammatory skin diseases, such as AD.
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Figure 1. Protein expression and activity of FAAH is upregulated upon Toll-like
receptor activation in immortalized (HPV-KER) and primary (NHEK) human
epidermal keratinocytes. (a–d) Western blot analysis of lysates of HPV-KERs (a) or
NHEKs (c) treated with LPS, LTA (5 and 10 lg/ml, respectively) or vehicle (24 h).
Two additional experiments yielded similar results. (b, d) Statistical analyses of the
above Western blot experiments (c: HPV-KER; d: NHEK). OD: optical density of the
FAAH bands normalized to the corresponding b-tubulin (TUBB) signals. Data are
presented as mean  SEM of 3 independent experiments regarding vehicle control
as 1 (solid line). *P < 0.05 vs. control group. (e-f) Measurement of FAAH activity
on HPV-KERs (e) and on NHEKs (f) following 24-h treatments with LTA (10 lg/ml)
or vehicle. Specific inhibition of FAAH activity ([3H]AEA hydrolysis) was achieved
with URB597 (100 nM). Data are expressed as mean  SEM of three independent
experiments each of them performed in triplicates. **, ***P < 0.01 and 0.001,
respectively; n.s.: non-significant difference.
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Figure 2. FAAH inhibitors exert significant anti-inflammatory actions both in vitro
and in vivo. (a-b) Q-PCR analyses of HPV-KERs following the indicated 24-h
treatments (LTA: 10 lg/ml; URB597: 100 nM; WOBE440: 100 nM; WOBE479:
200 nM). Data are presented using DDCT method regarding PPIA-normalized
mRNA expressions of the vehicle control as 1 (solid line). Data are expressed as
mean  SD of 3 independent determinations. Two additional experiments yielded
similar results. (c–d) Determination of the released cytokine concentration following
24-h treatments (LTA: 10 lg/ml; WOBE440: 100 nM; WOBE479: 200 nM). Data are
presented as mean  SEM of three independent determinations. One additional
experiment yielded similar results. (a–d) *P < 0.05 compared to the vehicle control.
#P < 0.05 compared the LTA-treated, FAAH inhibitor-free group. (e–f) Alterations
in total ear thickness (e) and in total disease score (f) following the indicated
treatments (tacrolimus: 0.1 [w/v]%; WOBE440 and 479: 1 [w/v]%). *, ** and
*** mark significant (P < 0.05, 0.01 or 0.001, respectively) differences of the
graphs with the same colour compared to the daily control group. N = 8–9
animals were investigated in each group.
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